期刊
BONE MARROW TRANSPLANTATION
卷 46, 期 6, 页码 892-898出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2010.197
关键词
acute GVHD; MTX; methylprednisolone
资金
- National Outstanding Young Scientist's Foundation of China [30725038]
- Program for Innovative Research Team in University [IRT 0702]
- Leading Program of Clinical Faculty
To study the efficacy and safety of a low dose of MTX combined with a low dose of methylprednisolone (MP) as a first-line therapy in the treatment of acute GVHD (aGVHD) after allogeneic hematopoietic SCT, 32 patients received i.v. MTX at a dose of 10 mg or oral MTX at a dose of 15 mg every 3-7 days (repeated at day 3 after the first dose and then at a weekly interval) combined with a low dose of MP (0.5 mg/kg/day) until a complete or partial response was achieved, or until treatment failure or intolerable side effects occurred. The overall treatment response rate was 81% (26/32 patients) and the response rate at day 28 was 75% (24/32 patients). The response rate for GVHD involving various organs was 88% (23/26) in the skin, 75% (3/4) in the liver and 81% (9/11) in the gut. Grade 3 toxicities occurred in only three patients presenting cytopenias. The estimated survival at 2 years was 77%. From this analysis, MTX in combination with a low dose of MP appears to be a well-tolerated, effective and inexpensive regime when used as a first-line treatment for aGVHD. Bone Marrow Transplantation (2011) 46, 892-898; doi: 10.1038/bmt.2010.197; published online 16 August 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据